1. Home
  2. NOTV vs QTTB Comparison

NOTV vs QTTB Comparison

Compare NOTV & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOTV
  • QTTB
  • Stock Information
  • Founded
  • NOTV 1974
  • QTTB 2015
  • Country
  • NOTV United States
  • QTTB United States
  • Employees
  • NOTV N/A
  • QTTB N/A
  • Industry
  • NOTV Biotechnology: Pharmaceutical Preparations
  • QTTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • NOTV Health Care
  • QTTB Health Care
  • Exchange
  • NOTV Nasdaq
  • QTTB Nasdaq
  • Market Cap
  • NOTV 28.7M
  • QTTB 25.1M
  • IPO Year
  • NOTV 1997
  • QTTB N/A
  • Fundamental
  • Price
  • NOTV $0.87
  • QTTB $2.10
  • Analyst Decision
  • NOTV Strong Buy
  • QTTB Hold
  • Analyst Count
  • NOTV 1
  • QTTB 7
  • Target Price
  • NOTV $5.00
  • QTTB $12.17
  • AVG Volume (30 Days)
  • NOTV 1.6M
  • QTTB 69.2K
  • Earning Date
  • NOTV 12-03-2025
  • QTTB 11-13-2025
  • Dividend Yield
  • NOTV N/A
  • QTTB N/A
  • EPS Growth
  • NOTV N/A
  • QTTB N/A
  • EPS
  • NOTV N/A
  • QTTB N/A
  • Revenue
  • NOTV $505,299,000.00
  • QTTB N/A
  • Revenue This Year
  • NOTV $5.64
  • QTTB N/A
  • Revenue Next Year
  • NOTV $5.16
  • QTTB N/A
  • P/E Ratio
  • NOTV N/A
  • QTTB N/A
  • Revenue Growth
  • NOTV 0.85
  • QTTB N/A
  • 52 Week Low
  • NOTV $0.66
  • QTTB $1.35
  • 52 Week High
  • NOTV $6.48
  • QTTB $28.66
  • Technical
  • Relative Strength Index (RSI)
  • NOTV 36.75
  • QTTB 41.18
  • Support Level
  • NOTV $0.77
  • QTTB $1.98
  • Resistance Level
  • NOTV $0.86
  • QTTB $2.15
  • Average True Range (ATR)
  • NOTV 0.13
  • QTTB 0.18
  • MACD
  • NOTV -0.01
  • QTTB -0.03
  • Stochastic Oscillator
  • NOTV 35.07
  • QTTB 28.46

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Share on Social Networks: